Trial Profile
A Phase II Neoadjuvant Trial of Sequential Doxorubicin and Docetaxel for the Treatment of Stage III Breast Cancer Measuring STAT Activation as a Predictor of Response to Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Doxorubicin (Primary) ; Filgrastim
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 04 Sep 2005 New trial record.